Literature DB >> 9792466

Regulation of interleukin-6 expression in human osteoblastic cells in vitro.

T Hierl1, I Börcsök, U Sommer, R Ziegler, C Kasperk.   

Abstract

Interleukin-6 (IL-6) is a potent stimulator of bone resorption which has been demonstrated in a variety of in vivo and in vitro models. We investigated the regulation of IL-6 secretion in primary human osteoblastic cells (HOC) in vitro by cytokines known to play an important role in coupling bone formation to bone resorption. HOC were isolated from healthy adults who underwent selective orthopedic surgery and treated with cytokines released in the bone microenvironment during coupling i.e Interleukin-1beta (IL-1beta), Tumor Necrosis Factor alpha (TNFalpha), Transforming Growth Factor beta1 and 2 (TGFbeta 1 and 2) and Endothelin-1 (ET-1). Furthermore, we determined whether systemically-acting steroid hormones of gonadal and adrenal origin as well as glucocorticoids affect the local regulation of IL-6 secretion in primary HOC. To examine the effects of different steroid hormones on IL-6 production, HOC were exposed to estradiol (E2), dihydrotestosterone (DHT), dehydroepiandrosterone (DHEA) and dexamethasone (Dexa) with and without a subsequent treatment of the HOC populations with cytokines. We observed that (1) IL-1beta and TNFalpha induced IL-6 in a dose and time-dependent fashion, (2) TGFbeta 1 and 2 enhanced basal and IL-1beta and TNFalpha induced IL-6 expression, (3) ET-1 elicited a dose-dependent stimulatory effect on IL-6 expression. (4) E2, DHT and DHEA alone and in combination with IL-1beta and TNFalpha elicited no reproducible dose-dependent effect on IL-6 production, whereas Dexa inhibited basal and IL-1beta and TNFalpha induced IL-6 expression dose dependently. In conclusion, IL-1beta, TNFalpha, TGFbeta 1 and 2 and ET-1 may participate in the regulation of bone resorption by stimulating IL-6 expression in HOC. Dexa inhibits the constitutive and cytokine stimulated IL-6 expression, whereas there is no in vitro evidence that sex steroids exert a major inhibitory effect on the osteoblastic secretion of IL-6 as demonstrated in a primary human bone cell model.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9792466     DOI: 10.1055/s-0029-1211993

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  6 in total

1.  Detection and characterization of endothelin in transformed human osteoblast cell culture medium.

Authors:  H C Lam; J K Lee; K H Lai
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

2.  Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures.

Authors:  C Méndez-Dávila; C García-Moreno; C Turbì; C de la Piedra
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 3.  DHEA and the skeleton (through the ages).

Authors:  C M Gordon; J Glowacki; M S LeBoff
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

4.  Preliminary studies on the effect of dehydroepiandrosterone (DHEA) on both constitutive and phytohaemagglutinin (PHA)-inducible IL-6 and IL-2 mRNA expression and cytokine production in human spleen mononuclear cell suspensions in vitro.

Authors:  D G Young; G Skibinski; A Skibinska; J I Mason; K James
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

5.  Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects.

Authors:  Hasan Hilmi Muratli; Levent Celebi; Onur Hapa; Ali Biçimoğlu
Journal:  BMC Musculoskelet Disord       Date:  2005-09-20       Impact factor: 2.362

6.  Duffy antigen receptor for chemokines regulates post-fracture inflammation.

Authors:  Charles H Rundle; Subburaman Mohan; Bouchra Edderkaoui
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.